Maintaining normal levels of ionized calcium during citrate-based renal replacement therapy is associated with stable parathyroid hormone levels

Nephron - Clinical Practice

Volumn 124, Issue 1-2, 2013, Pages 124-131

  Raimundo, Mário ^a,b   Crichton, Siobhan ^a   Lei, Katie ^a   Sanderson, Barnaby ^a   Smith, John ^a   Brooks, John ^a   Ng, Josephine ^a   Lemmich Smith, Joanna ^a   McKenzie, Catherine ^a   Beale, Richard ^a   Dickie, Helen ^a   Ostermann, Marlies ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b HOSPITAL DE SANTA MARIA   (Portugal)

Author keywords

Acute kidney injury; Citrate; Continuous renal replacement therapy; Parathyroid hormone

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CALCIUM ION; CITRIC ACID; MAGNESIUM; PARATHYROID HORMONE; PHOSPHATE; VITAMIN D;

ACUTE KIDNEY FAILURE; ADULT; AGED; ARTERIAL PH; ARTICLE; CALCIUM BLOOD LEVEL; CLINICAL ARTICLE; CONTINUOUS HEMODIALYSIS; CRITICALLY ILL PATIENT; FEMALE; HUMAN; HYPERPARATHYROIDISM; HYPOCALCEMIA; LABORATORY TEST; MAGNESIUM BLOOD LEVEL; MALE; OBSERVATIONAL STUDY; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROID HORMONE RELEASE; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RENAL REPLACEMENT THERAPY; SERUM; ARTIFICIAL KIDNEY; CITRATE BASED RENAL REPLACEMENT THERAPY; CONTINUOUS RENAL REPLACEMENT THERAPY; HEMODIALYSIS MACHINE;

AGED; ANTICOAGULANTS; CALCIUM; CITRIC ACID; FEMALE; HUMANS; IONS; KIDNEY FAILURE, CHRONIC; MALE; PARATHYROID HORMONE; RENAL REPLACEMENT THERAPY; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; THROMBOSIS; TREATMENT OUTCOME;

EID: 84886738099     PISSN: None     EISSN: 16602110     Source Type: Journal    
DOI: 10.1159/000355860     Document Type: Article

References (29)

1. Oudemans-Van Straaten HM, Bosman RJ, Koopmans M, van der Voort PH, Wester JP, van der Spoel JI, Dijksman LM, Zandstra DF: Citrate anticoagulation for continuous venovenous hemofiltration. Crit Care Med 2009; 37: 545-552.
2. Hetzel GR, Schmitz M, Wissing H, Ries W, Schott G, Heering PJ, Isgro F, Kribben A, Himmele R, Grabensee B, Rump LC: Regional citrate versus systemic heparin for anticoagulation in critically ill patients on continuous venovenous haemofiltration: a prospective randomized multicentre trial. Nephrol Dial Transplant 2010; 26: 232-239.
3. Betjes MG, van Oosterom D, van Agteren M, van de Wetering J: Regional citrate versus heparin anticoagulation during venovenous hemofiltration in patients at low risk for bleeding: similar hemofilter survival but significantly less bleeding. J Nephrol 2007; 20: 602-608.
4. Kutsogiannis DJ, Gibney RT, Stollery D, Gao J: Regional citrate versus systemic heparin anticoagulation for continuous renal replacement in critically ill patients. Kidney Int 2005; 67: 2361-2367.
5. Monchi M, Berghmans D, Ledoux D, Canivet JL, Dubois B, Damas P: Citrate vs. heparin for anticoagulation in continuous venovenous hemofiltration: a prospective randomized study. Intensive Care Med 2004; 30: 260-265.
6. Zhang Z, Hongying N: Efficacy and safety of regional citrate anticoagulation in critically ill patients undergoing continuous renal replacement therapy. Intensive Care Med 2006; 38: 20-28.
7. Oudemans-van Straaten HM. Wester JPJ, de Pont ACJM, Schetz MR: Anticoagulation strategies in continuous renal replacement therapy: can the choice be evidence based? Intensive Care Med 2006; 32: 188-202.
8. Oudemans-Van Straaten HM: Anticoagulation for renal replacement therapy: heparin or citrate; in Kuhlen R, Moreno R, Ranieri M, Rhodes A (eds): Controversies in Intensive Care Medicine. Berlin, Medizinische Wissenschaftliche Verlagsgesellschaft, 2008, pp 153- 161.
9. Oudemans-van Straaten, Kellum JA, Bellomo R: Clinical review: anticoagulation for continuous renal replacement therapy - heparin or citrate? Critical Care 2011; 15: 202.
10. Kidney Disease, Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group: KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl 2012; 2: 1-138.
11. Gabutti L, Marone C, Colucci G, Duchini F, Schönholzer C: Citrate anticoagulation in continuous venovenous hemodiafiltration: a metabolic challenge. Intensive Care Med 2002; 28: 1419-1425.
12. Brown EM, Macleod RJ: Extracellular calcium sensing and extracellular calcium signaling. Physiol Rev 2001; 81: 239-297.
13. Wang PL, Meyer MM, Orloff SL, Anderson S: Bone resorption and 'relative' immobilization hypercalcemia with prolonged continuous renal replacement therapy and citrate anticoagulation. Am J Kidney Dis 2004; 44: 1110- 1114.
14. Van der Voort PH, Postma SR, Kingma WP, Boerma EC, de Heide LJ, Bakker AJ: An observational study on the effects of nadroparinbased and citrate-based continuous venovenous haemofiltration on calcium metabolism. Blood Purif 2007; 25: 267-273.
15. Brain M, Parkes S, Fowler P, Robertson I, Brown A: Calcium flux in continuous venovenous haemodiafiltration with heparin and citrate anticoagulation. Crit Care Resusc 2011; 13: 72-81.
16. Carlstedt F, Lind L, Rastad J, Stjernström H, Wide L, Ljunghall S: Parathyroid hormone and ionized calcium levels are related to the severity of illness and survival in critically ill patients. Eur J Clin Invest 1998; 28: 898-903.
17. Lind L, Carlstedt F, Rastad J, Stiernström H, Stridsberg M, Lunggren O, Wide L, Larsson A, Hellman P, Ljunghall S: Hypocalcemia and parathyroid hormone secretion in critically ill patients. Crit Care Med 2000; 28: 93- 99.
18. Brown EM: Extracellular Ca 2+ sensing, regulation of parathyroid cell function, and role of Ca 2+ and other ions as extracellular (first) messengers. Physiol Rev 1991; 71: 371-411.
19. Morgera S, Schneider M, Slowinski T, Vargas- Hein O, Zuckermann-Becker H, Peters H, Kindgen-Milles D, Neumayer HH: A safe citrate anticoagulation protocol with variable treatment efficacy and excellent control of the acid-base status. Crit Care Med 2009; 37: 2018- 2024.
20. Apsner R, Gruber D, Hörl WH, Sunder-Plassmann G: Parathyroid hormone secretion during citrate anticoagulated hemodialysis in acutely ill maintenance hemodialysis patients. Anesth Analg 2004; 99: 1199-1204.
21. Smith LM, Cuthbertson B, Harvie J, Webster N, Robins S, Ralston SH: Increased bone resorption in the critically ill: association with sepsis and increased nitric oxide production. Crit Care Med 2002; 30: 837-840.
22. Aris RM, Lester GE, Ontjes DA: Bone loss physiology in critically ill patients. Chest 1998; 114: 954-955.
23. Nierman DM, Mechanick JI: Bone hyperresorption is prevalent in chronically critically ill patients. Chest 1998; 114: 1122-1128.
24. Haden ST, Brown EM, Hurwitz S, Scott J, El- Haji Fuleihan G: The effects of age and gender on parathyroid hormone dynamics. Clin Endocrinol (Oxf) 2000; 52: 329-338.
25. Joborn H, Hjemdahl P, Larsson PT, Lithell H, Olsson G, Wide L, Bergström R, Ljunghall S: Effects of prolonged adrenaline infusion and of mental stress on plasma minerals and parathyroid hormone. Clin Physiol 1990; 10: 37- 53.
26. Brown EM, Hurwitz S, Woodard CJ, Aurbach GD: Direct identification of beta-adrenergic receptors on isolated bovine parathyroid cells. Endocrinology 1977; 100: 1703-1709.
27. Hocher B, Armbruster FP, Stoeva S, Reichetzeder C, Grön HJ, Lieker I, Khadzhynov D, Slowinski T, Roth HJ: Measuring parathyroid hormone (PTH) in patients with oxidative stress - do we need a fourth generation parathyroid hormone assay? PLoS One 2012; 7:e40242.
28. Quarles LD, Lobaugh B, Murphy G: Intact parathyroid hormone overestimates the presence and severity of parathyroid-mediated osseous abnormalities in uremia. J Clin Endocrinol Metab 1992; 75: 145-150.
29. Chen Y, Hou J, Chen G, Lin H, Lin H, Chu X, Zeng J, Chen C, Lin J, Dettke M: Calcium supplementation attenuates citrate-related changes in bone metabolism: a placebo-controlled crossover study in healthy volunteers. Bone 2011; 49: 506-512.